Medication info
Recanuro Capsule 150 mg (Pregabalin)

Recanuro Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a white upper part and a white lower part containing a powder that is white to pale yellow.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201109295 · Approved 2011.10.31 · Insurance code 671805170

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures in epilepsy, treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adult patients. It is also effective as an adjunctive treatment for partial seizures in patients with epilepsy. Additionally, it helps improve symptoms of fibromyalgia. It is a medication used to manage significant central nervous system-related pain and seizures. This drug is used for neuropathic pain, seizures, and improving fibromyalgia symptoms.

How to take

Adult dose

This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: Supplemental dose refers to an additional dose administered once. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so patients should carefully monitor for mood changes or unusual behaviors during treatment. Patients with hypersensitivity to this medication or genetic issues such as lactose intolerance should not take it. Diabetic patients may need to adjust the dosage of blood glucose control medications due to weight gain, and if symptoms of angioedema occur, treatment should be stopped immediately. Elderly patients should be careful due to the risk of falls or injuries from dizziness or drowsiness. Vision blurring or changes in vision may occur during treatment, so patients should consult healthcare professionals if these symptoms arise. Before administering this medication alone, care should be taken not to suddenly discontinue any previously prescribed anti-epileptic medications. When discontinuing the medication, withdrawal symptoms such as insomnia, headaches, and anxiety may occur, and dosage should be gradually reduced as directed by a healthcare professional. Patients with a history of substance abuse may have a higher risk of abuse with this medication, so caution is advised during use. Patients with impaired renal function may require dose adjustments, and those with heart diseases should also use caution while taking it. Combining this medication with opioids may enhance central nervous system depressant effects, leading to risks such as respiratory depression, so care should be taken. In early pregnancy, it can pose risks to the fetus, so pregnant women are advised not to take it, and women of childbearing age should use effective contraception. Breastfeeding women should discuss with healthcare professionals about stopping breastfeeding or the medication since this drug can pass into breast milk. Care should be taken after taking this drug when driving or operating hazardous machinery due to the risk of accidents from dizziness or drowsiness. In case of overdose, symptoms such as confusion, drowsiness, and seizures may appear, necessitating immediate medical attention, and blood dialysis may be required if necessary. This medication should be stored out of reach of children and should not be transferred to other containers for safety.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial edema
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 175 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • melancholy
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • impaired respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • decreased oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • poor appetite
  • hypoglycemia
  • confusion
  • directional disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hypersexuality
  • restlessness
  • mood fluctuation
  • emotional lability
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • abnormal motor coordination
  • equilibrium disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremor
  • dysarthria
  • sensory disturbances
  • sensory decrease
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech impairment
  • turgor spasms
  • decreased reflexes
  • movement abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypomobility
  • olfactory disturbances
  • taste loss
  • writing disturbance
  • diplopia
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusion state
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to keep the storage temperature between 15°C and 30°C to maintain the drug's efficacy.

Appearance and packaging

Appearance

A hard capsule with a white upper part and a white lower part containing a powder that is white to pale yellow.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.